Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,413 across all filing types
Latest filing 2025-07-31 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release dated July 31, 2025, about Q2 sales and EPS growth and updated sales guidance. The document is short (1428 characters) and primarily serves to file the press release with the SEC. It does not contain detailed financial statements or comprehensive analysis typical of an Interim/Quarterly Report (IR). Instead, it is a regulatory filing to disclose material information. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-07-31 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes references to press releases about product approvals and orphan drug designation, but does not contain financial statements or detailed financial analysis. The document length is short (1506 characters) and it mainly serves to report recent press releases. There is no indication that this is a full annual or interim report, audit report, earnings release, or other detailed financial filing. It is a regulatory filing providing updates and disclosures as required by the SEC for foreign issuers. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2025-07-31 English
Communiqué de presse : T2 : croissance à deux chiffres desventes, nette progression du BNPA des activités ; perspectives de ventes 2025 revues à la hausse avec une croissance désormais attendue dans l
Earnings Release Classification · 100% confidence The document is a press release from Sanofi dated July 31, 2025, detailing financial results for the second quarter (T2) and first half (S1) of 2025. It includes key performance indicators such as sales growth, earnings per share (BNPA), R&D expenses, and business development updates. As it is the primary announcement of quarterly financial results, it falls under the Earnings Release category. Q2 2025
2025-07-31 French
Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range
Earnings Release Classification · 100% confidence The document is a detailed quarterly financial results announcement from Sanofi for Q2 2025. It contains key financial highlights, sales performance by geography and segment, business operating income, and management commentary on guidance and pipeline progress. It is clearly an initial announcement of quarterly financial results rather than a full interim report or a simple publication notice, fitting the definition of an Earnings Release. Q2 2025
2025-07-31 English
Sanofi - Rapport semestriel 2025
Interim / Quarterly Report Classification · 100% confidence The document is a 'Rapport financier semestriel 2025' (Half-year financial report) for Sanofi. It contains comprehensive consolidated financial statements (balance sheets, income statements, cash flow statements) for the six-month period ending June 30, 2025, along with management discussion and analysis and auditor reports. It is a substantive financial report rather than an announcement or certification, fitting the definition of an Interim/Quarterly Report. H1 2025
2025-07-31 French
Regulatory Filings 2025
Regulatory Filings
2025-07-30 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.